Vicore's Phase 2b ASPIRE Trial of Buloxibutid in IPF Passes Pre-Planned Futility Analysis and Remains on Track for Mid-2027 Topline Results
Vicore Pharma to Participate in the Chardan Healthcare Conference
Jefferies Initiates Coverage On Vicore Pharma Holding with Buy Rating, Announces Price Target of $25
Increase in Number of Shares and Votes in Vicore Pharma
Vicore Pharma Holding AB (publ) (VCRE) Presents at European Respiratory Society (ERS) Congress - Slideshow
Vicore Pharma to Participate in Upcoming Healthcare Conferences
Vicore Pharma to Participate in the Leerink Therapeutics Forum
Vicore Pharma Appoints Rob Slack as Chief Scientific Officer
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.
